CHICAGO -- Adding a novel cereblon E3 ligase modulation (CELMoD) drug to a standard multiple myeloma regimen significantly improved progression-free survival (PFS) in a vulnerable population of patients with relapsed or refractory disease, a phase III trial showed.
In participants largely refractory to lenalidomide (Revlimid) and an anti-CD38 antibody, median PFS reached 18 months with the triplet of mezigdomide plus carfilzomib (Kyprolis) and dexamethasone, as compared with 8.3 months with the latter two drugs alone (HR 0.48, 95% CI 0.36-0.63, P<0.0001), reported Paul Richardson, MD, of the Dana-Farber Cancer Institute in Boston.
"Oral mezigdomide combined with weekly IV carfilzomib is a potential new standard of care in relapsed/refractory disease and, most importantly, can be easily used across diverse care settings, including community practice," he said during a late-breaking presentation of the SUCCESSOR-2 trial at the American Society of Clinical Oncology (ASCO) annual meeting.
The triplet regimen substantially improved response rates, induced deeper responses, was also associated with superior second PFS, and the safety profile was manageable with dose modification and growth factors, according to Richardson.
